AAFP: EHRs ‘suck the life out of everyone that uses them’

A blog post from Shawn Martin, senior vice president of advocacy, practice advancement and policy at the American Academy of Family Physicians, argued the electronic health record (EHR) industry has failed to live up to promises to reduce costs, improve care and help avert dangerous medical errors—and what it needs now is a disruptive infusion of competition.

Martin said he often hears outright disdain for EHRs from all physicians. Looking back at the initial push begun by President George W. Bush in 2004 through the “Promoting Innovation and Competitiveness” campaign, Martin determined that not only have EHRs “failed epically” to meet expectations, but created new problems—like “a plethora of cottage industries and consultants” and heavily contributed to physician burnout.

“I struggle to find an articulate and elegant way to describe what is so frustrating about electronic health records, but I think I have found a way to do so succinctly—they suck,” Martin wrote. “They suck as products, and they suck the life out of everyone that uses them.”

The solutions may not be coming from within, Martin wrote, with powerful EHR vendors and providers settling for incremental improvements while innovators can’t break into the space. The industry “desperately” needs innovation which may be disruptive to those entrenched forces, which the AAFP believes can come from a combination of expanding interoperability to make health IT easier for new entrants, standardizing clinical data and reducing requirements from regulators or payers “which do not add clinical value.”

Read the full blog at the link below:  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.